Wednesday, June 25, 2014

Buying medicines online? Commission introduces logo to make sure consumers are safe


With Europeans increasingly buying medicines online, how can we be sure that an online pharmacy is authentic and safe?

Today, the Commission adopts an implementing Regulation under the Falsified Medicinal Products Directive (2011/62/EU) which sets out the design for a common logo for online pharmacies, and the technical requirements for ensuring its authenticity.

The logo will fully be available in second half of 2015.

Tonio Borg, European Commissioner for Health, said: "When buying medicines online, consumers must be aware that unless they buy from legally-operating online medicine suppliers, they run the risk of buying medicines that are falsified. Falsified medicines can be ineffective, harmful or even deadly. The Commission has established a common logo for online pharmacies so consumers can stay safe."

This is the logo to look out for on the homepage of an online pharmacy. The rectangle on the middle left side will have the flag of the EU country where the online pharmacy is established, and the text will be translated into the official language/s of that country.

How does it work?

First, look for the logo on the website through which you are considering buying medicines and click on it. You should be taken to the national regulatory authority website, which lists all legally operating online pharmacies and other legally authorised retailers of medicines. Check that the pharmacy is listed. Then continue with your purchase. If not listed, do not buy from that website. Use one of the legitimate medicine retailers listed on your national regulatory authority’s website. 

When will it start to appear? 

The Regulation should enter into force in the next four to six weeks. Member States have one year to prepare for its application. The European Commission is providing national authorities with a Communication Toolkit to support them with the preparation of national awareness campaigns which are required by the Falsified Medicines Directive.

The toolkit and more information on falsified medicines is available here: http://ec.europa.eu/health/human-use/falsified_medicines/index_en.htm

Source

Europa.eu

Tuesday, June 24, 2014

Joan Peppard elected as next EAHP President


Joan Peppard has been elected as the next President of the European Association of Hospital Pharmacists (EAHP), commencing a 3 year term of office from June 2015. She will now serve one year as President Elect during the final 12 months of Dr Roberto Frontini’s Presidency of the Association.

The election took place at the General Assembly of the EAHP in Sofia. The General Assembly is the annual occasion at which the 34 member countries of EAHP meet in person to determine policy, elect the Board, scrutinise the activities of the Association and conduct other decision making activity.

Joan, a chief pharmacist in a hospital in the Irish midlands, currently serves on the EAHP Board as Director of Professional Development and has twice been the head of the Hospital Pharmacists Association of Ireland in the position of President. Prior to joining the EAHP Board Joan was for many years one of the lead delegates for Ireland within the EAHP annual General Assembly, and played an active role in the conduct of EAHP educational and research activities at the national level.

Speaking after her election, Joan Peppard, President-Elect of EAHP said: “It is with a sense of great humility that I begin to take on the primary leadership role of the EAHP, knowing that under the stewardship of predecessors a real momentum of energy and experience has been established to make EAHP the driver for hospital pharmacy practice improvement across Europe that it is today. With the new European Statements of Hospital Pharmacy recently agreed between the profession, patients and other healthcare professionals, the number one challenge for the forthcoming EAHP Board is evident – how to turn that clear vision for the future of the profession into a reality in every European country. Working with my colleagues on the Board, the secretariat and our dedicated membership, I know we have the commitment, insight and enthusiasm to achieve it. I again thank members for the confidence they have placed in me and look forward to working with them in delivering our shared aspirations for the profession we all love.”

Dr Roberto Frontini, President of EAHP added: “Knowing very well Joan’s professional background, and her proven ability to make change happen on the ground, even in the most difficult practice environments, I am completely assured EAHP will continue to go from strength to strength in the achievement of its mission under her leadership. I’m therefore looking forward to assisting in the handover period, and introducing her personally to the many partner, friend and allied organisations we work with in ensuring the continuous improvement of all that the hospital pharmacist does across our member countries."

Source

EAHP

Monday, June 16, 2014

Final Opinion on Nanosilver: safety, health and environmental effects and role in antimicrobial resistance


Today, the European Commission and its non-food Scientific Committee on Emerging and Newly Identified Health Risks, SCENIHR, published the final opinion on "Nanosilver: safety, health and environmental effects and role in antimicrobial resistance".

The aim of this opinion is to assess whether the use of nanosilver, in particular in medical care and in consumer products, could result in additional risks compared to more traditional uses of silver and whether the use of nanosilver to control bacterial growth could result in resistance of micro-organisms.

SCENIHR concludes that the widespread (and increasing) use of silver containing products implicates that both consumers and the environment are exposed to new sources of silver. Human exposure is direct (food, hand-to-mouth contact, skin) and may be life long; while in the environment silver nanoparticles may be a particularly effective delivery system for silver to organisms in soil, water and sediment and may act as sources of ionic silver over extended periods of time. Therefore, additional effects caused by widespread and long term use of silver nanoparticles cannot be ruled out.

Regarding the hazard associated with the dissemination of the resistance mechanism following the use of silver nanoparticles, more data are needed to better understand bacterial response to ionic silver and silver nanoparticles exposure.

To read the Opinion in full 
For more information on the Commission’s independent scientific committees

Content of the opinion In 2012, the Scientific Committee on Emerging and Newly Identified Health Risks, SCENIHR, was asked to formulate an Opinion on Nanosilver: safety, health and environmental effects and role in antimicrobial resistance. This was mainly due to the concern with regard to health risks associated with the use of nanosilver.

The aim of this opinion is to assess whether the use of nanosilver, in particular in medical care and in consumer products, could result in additional risks compared to more traditional uses of silver and whether the use of nanosilver to control bacterial growth could result in resistance of micro-organisms.

SCENIHR concluded that the widespread (and increasing) use of silver containing products implicates that both consumers and the environment are exposed to new sources of silver. Human exposure is direct (food, hand-to-mouth contact, skin) and may be life long; while in the environment silver nanoparticles may be a particularly effective delivery system for silver to organisms in soil, water and sediment and may act as sources of ionic silver over extended periods of time. Therefore, additional effects caused by widespread and long term use of silver nanoparticles cannot be ruled out.

Regarding the hazard associated with the dissemination of the resistance mechanism following the use of silver nanoparticles, no studies are available at this moment, representing a serious gap of knowledge. Since other nanoparticles have been shown to substantially increase the horizontal gene transfer between bacteria – which is extremely relevant for developing resistance – the potential of silver nanoparticles to induce similar effects should be given particular attention. More data are needed to better understand bacterial response to ionic silver and silver nanoparticles exposure. Since the mechanisms resulting in silver nanoparticles resistance are not well understood, it is not possible to estimate at this time whether or not resistance of microorganisms will increase and spread in view of a more widespread use of silver nanoparticles in products.

Source

European Commission

Wednesday, May 28, 2014

ePrescription and personal eHealth navigator for all Europeans


"Give health an e-Chance": Under this slogan the eHealth Forum 2014 took place in Athens on May 12-14. Amongst the nearly 1300 visitors were Greek Health Minister Adonis Georgiadis and two European Commissioners: Tonio Borg (Health & Consumers) and Neelie Kroes (Digital Agenda) who suggested we could all use a "personal eHealth navigator" and electronic prescriptions.

Commissioner and Vice-President Neelie Kroes said at the opening of the conference: "Imagine if there were new tools that could fix the well-known problems faced by health systems. We'd be crazy to turn our backs on them. We'd be crazy not to do everything we could to promote them, invest in them, learn about them. Well – we now do have those tools."
Health costs fell by 30% in Greece
She gave some examples: "In Italy, eHealth tools have saved one euro in every 9 spent on healthcare. In Estonia citizens can go online to review their own records, consent to procedures, check up on prescriptions. Used by almost half of citizens, 80% of prescriptions, 95% of doctors, and 100% safely and securely. Here in Greece, average costs fell by 30% since ePrescriptions were introduced - an innovation which also fights fraud and cuts over-prescribing."
Mrs Kroes announced: "I want to put health in the hands of the European citizens". She proposed giving everyone a "Personal Health Navigator" to help people find their nearest doctor, pharmacy or hospital and to give them access to their personal health data and trustworthy health information.
"Our shared ambition should be that we ensure every European citizen to be digital, connected and healthy. And that Europe will take this opportunity and gain the lead in this growing and highly innovative market", Mrs Kroes concluded her speech.
ePrescriptions everywhere in Europe?
Greek Health Minister Adonis Georgiadis emphasized  that Greece has showcased best practices in the area of electronic prescribing. He noted, "if there were no ePrescriptions, the health system in our country would have collapsed", adding that eHealth is not a luxury but a necessity.
In this context, both Georgiadis and Health Commissioner Tonio Borg stressed the need to incorporate ePrescriptions into the national strategies of all EU countries.
Commissioner Borg noted in his speech that this would be discussed the following day by the high-level eHealth Network, a group of representatives of all EU Member States: "Tomorrow, the Network will discuss new guidelines for ePrescriptions. [...] These guidelines seek to facilitate the interoperability of electronic prescriptions across borders, so that electronic prescriptions can be processed easily in any European Union country; so that patients can always get the medicines they need."
At the Forum, the eHealth Network discussed a first draft of EU ePrescription guidelines, of which the adoption is expected in November 2014.

Sources


Thursday, May 22, 2014

European Patients' Rights Day: 10 benefits the EU brings to patients


A high level of health protection; the right to benefit from medical treatment; access to healthcare - preventive, diagnostic and curative treatment regardless of financial means, gender or nationality. These principles are enshrined in the European Union's Treaty1 and its Charter of Fundamental Rights2 and the EU institutions are bound to them in their actions. On European Patients' Rights Day, let's take a look at some of the benefits of being a patient in the European Union. As an EU citizen, you can expect:
1) To receive healthcare when visiting another EU country
If you fall ill unexpectedly during a trip to another EU country and need to visit a doctor, there's no need to cut short your visit to return home for treatment. Take your European Health Insurance Card with you to a local doctor.
2) To be reimbursed for healthcare sought in another EU country
Should you decide to receive medical treatment in other EU country you can be reimbursed for it at home, under certain circumstances, and normally up to the amount you would be reimbursed in your home country for the same treatment. In some cases, your home country may require you to seek prior authorisation before travelling for treatment.
3) To receive information on safety and quality standards in EU countries
A national contact point in each Member State shall provide information to patients on their rights to healthcare across Europe. Access to information on the quality and safety of care will allow you to make informed decisions.
These contact points can also provide information on the European Reference Networks where you can receive highly specialised healthcare in the case of complex, low prevalence or rare conditions.
4) To be treated by qualified healthcare professionals
Patients have the guarantee that whether receiving medical care in their home country or another EU country, they will be treated by healthcare professionals – be they doctors, dentists, nurses, midwives or pharmacists, who have met EU-wide minimum requirements.
Patients will, upon request, receive information from their national contact point about a healthcare provider's right to practice.
5) To get a copy of your medical records
When you are treated, your healthcare provider must make a medical record of the treatment provided. As a patient you have the right to a copy of this medical record in order to secure continuity of care and be treated by a doctor of your choice, also if you continue treatment in another Member State.
6) To have your prescription recognised in all EU Countries
The Commission has set rules on mutual recognition of prescriptions between Member States and on a minimum list of elements to be included in a cross border medical prescription.
As a patient, when travelling to another EU country it is reassuring to know that your prescription can be recognised at your destination. To avoid delays, interruptions in treatment and extra costs, ask your health professional for a cross border prescription before you leave.
7) To be treated with safe and effective medicines
Medicines must be authorised by the Member States or the European Commission before they can be placed on the EU market. This ensures patients are treated with medicines that are in compliance with strict standards on quality, safety and efficacy.
Once a medicinal product has been authorised in the Union and placed on the market, its safety is monitored during its entire lifespan to ensure that, in case of adverse reactions, appropriate action is taken swiftly, including additional warnings, restrictions of use or even withdrawal of the product.
8) To be able to report suspected side effects of medicines
As a patient, you have the right to report any adverse reactions to medicines you are taking directly to your national authorities. You can also do so through your doctor, pharmacist, nurse or other healthcare professional.
Medicines for which additional monitoring is considered necessary have a black inverted triangle in the package leaflet, along with information on how to report suspected adverse events through the national reporting system.
9) To be treated with safe medical devices
EU rules on medical devices, varying from simple bandages to the most sophisticated life-support machines, aim to ensure a high level of patient safety and rapid access to innovative technologies.
10) To benefit from common high standards of quality for blood, organs, tissues and cells
To guarantee quality and patient safety, the EU has developed common rules that apply across the EU to ensure that all donated human material is safe and carefully screened to prevent transmission of disease, for example HIV or hepatitis.
In addition, the EU funds projects and actions that support national authorities in training their inspectors, improving their vigilance systems as well as the organisation of and access to national transfusion and transplantation services.
For more information:
Website of Commissioner Borg:

European Patients' Rights Day: 10 benefits the EU brings to patients

European Commission - MEMO/14/341   12/05/2014

Source

http://europa.eu/

Friday, May 16, 2014

New European Statements of Hospital Pharmacy agreed by patients, healthcare professionals and hospital pharmacists


A robust set of hospital pharmacy practice standards for Europe has been agreed at an international Summit in Brussels. These standards should be met across European health systems to ensure safe, effective and optimal use of medicines in collaboration with multi-disciplinary teams. 

The standards were agreed at European Hospital Pharmacy Summit which concluded on Thursday 15th May, and was attended by more than 100 persons. 

The statements were subject to open Delphi consultation with national hospital pharmacy associations, European patient groups, doctors and nursing organisations. The same organisations then gave their final joint approval to each statement individually by a weighted voting method at the Summit event. 

Results of Summit votes HERE. 

A full summary of the Summit proceedings and the formation of the statements will be made available in the European Journal of Hospital Pharmacy. EAHP and its national member associations now look forward to working with national health systems to bring about the full achievement of the European Statements of Hospital Pharmacy in every European country. 

The European Statements of Hospital Pharmacy are available HERE.

Source

EAHP